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Abstract
Background: The smell sense reduction was considered to represent the potentially warning of early stage of
neurodegenerative disorders. The Shanghai Aging Study provided us a unique opportunity to explore the
association between olfactory identification (OI) and cognitive function among community-dwelling elderly in
China.
Methods: OI of each participant was measured by the 12-item identification tests from Sniffin’ Sticks Screening test
(SSST-12). Participants with mild cognitive impairment (MCI) were diagnosed by Petersen criteria. We used the
logistic regression analysis to explore the association between OI scores and cognitive function by adjusting
potential confounders.
Results: Among 1782 non-demented participants, 345 (19.4 %) participants were diagnosed as MCI. The mean OI
score for participants with MCI [7.1 (SD 2.3)] was significantly lower than that for those with normal cognition [8.2
(SD 2.0), P < 0.0001]. After adjusted for age, gender, education, lifestyles, medical history, Apolipoprotein E genotype,
lower OI score was found to be an independent influence factor related to MCI (OR 1.19, 95 % CI 1.11–1.27).
Conclusions: Our study suggests that poor OI may be associated with MCI in elderly population. Further
prospective studies may confirm the OI as a reliable and early marker predicting the decline of cognitive function.
Keywords: Olfactory identification, Mild cognitive impairment, Community-based study, Elderly
Background
Olfactory function is an important role in health and be-
havior because it may be a valid marker of the integrity
of the aging brain. The prevalence and severity of olfac-
tory dysfunction increase substantially with aging. Olfac-
tory dysfunction represents an important clinical
symptom suggestive of early stage of neurodegenerative
disorders, including Parkinson’s disease (PD) [1].
A series of community-based and hospital-based stud-
ies in western population have demonstrated that in
older adults, impaired olfactory function was closely
associated with the decline of cognitive functions, espe-
cially Alzheimer’s disease (AD) in the preclinical stage,
although this dysfunction is more likely to be due to
problems of olfactory identification (OI) than detection
[2–6]. As a transient condition, mild cognitive impair-
ment (MCI) is gaining more attention. It occurs along
the progression from normal aging to dementia, so it
comprises a broad clinical spectrum of pre-dementia
stages [7]. It was also reported that in MCI, olfactory
impairment may herald progression to dementia [8–10].
There was no general standard test for olfactory be-
cause of the cultural differences in diverse regions. Mod-
ern tests for OI include the Connecticut Chemosensory
Clinical Research Center Test (CCCRCT), University of
Pennsylvania Smell Identification Test (UPSIT), Cross-
Cultural Smell Identification Test (CC-SIT), Pocket
Smell Test (PST), Odorant confusion matrix, Biolfa
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olfactory test, Sniffin’ Sticks (SS), Smell Disketts Test,
Scandinavian Odor-identification test (SOIT), and San
Diego Odor Identification Test (SDOIT) in western
countries [11]. As in Chinese population, only studies in
Hongkong have been conducted to investigate the ap-
plicability of the OI and threshold tests across the
Chinese culture [12, 13].
China has one of the fastest ageing in the world.
According to the 2014 census, the number of people
aged 60 years and older was 212 million, occupying
15.5 % of the population [14]. So far in mainland China,
no large-sampled population-based study was conducted
to obtain the epidemiological data related to olfactory
function in the elderly, and the previous reports were
very limited from just hospital-based studies [12, 15].
The Shanghai Aging Study was a community-based
cohort study for investigating the progression of cogni-
tive decline in Chinese elderly [16]. With a study design,
operational procedures and diagnostic criteria similar to
most cohort studies in developed countries, the
Shanghai Aging Study is recognized the first epidemio-
logic study conducted in mainland China. The Sniffin’
Sticks Smell Test -12 (SSST-12) is a rapid, portable,
suited for repetitive and inexpensive screening of OI in a
population-based study [17]. By using it, we have a
unique opportunity to identify the association between




The Shanghai Aging Study was designed to establish a
prospective community-based cohort with elderly in
downtown Shanghai, China. Eligible participants were reg-
istered residents aged 60 or older in Jingansi community,
able to communicate and accept physical and cognitive
examinations, and they were not suffered from mental re-
tardation or schizophrenia based on their medical records.
Recruitment procedures were reported elsewhere [18].
According to the objective of the current study, under-
lying participants were excluded if they were 1) undergo-
ing maxillofacial surgery, with pathologies of the nose and
paranasal sinuses (rhinosinusitis and polyposis, allergic
rhinitis); 2) with chronic obstructive pulmonary disease
(eg. asthma, chronic sinusitis, etc.), or acute upper respira-
tory tract infection within 1 week; 3) with dementia or
other severe neurological diseases based on their medical
record or diagnosed by neurologists; 4) alcohol and drug
abuse, which may alter olfaction.
Clinical interview
Participants were interviewed face-to-face by trained re-
search nurses to obtain information on their demographic
characteristics, including age, gender, education, lifestyle
factors (such as living alone, cigarette smoking and alcohol
drinking). History of chronic diseases, such as physician-
diagnosed hypertension, diabetes, and heart disease
(including coronary artery disease and arrhythmia), were
asked and confirmed from their medical records. Each
participant was examined by neurologists for motor re-
sponses and reflexes. Neurologists were assigned to ad-
minister the Zung Self-Rating Anxiety Scale (ZSAS) and
the Center for Epidemiologic Studies Depression Scale
(CESD) for each participant to indicate his mood episode
within the past week. Anxiety and depression were deter-
mined if ZSAS >44 and CESD ≥ 16 [19, 20]. Neurologists
also administered the Clinical Dementia Rating (CDR)
[21, 22] and Brody Activity of Daily Living (ADL) [23]
scale to obtain information on cognitive complaints and
activities of daily living, which were used for the diagnosis
of cognitive function.
Neuropsychological assessments
Cognitive function of each participant was tested by a
neuropsychological test battery, which covers domains
of global cognition, executive function, spatial construc-
tion function, memory, language, and attention. The
battery contained: 1) Mini Mental State Examination
(MMSE); 2) Conflicting Instructions Task (Go/No Go
Task); 3) Stick Test; 4) Modified Common Objects
Sorting Test; 5) Auditory Verbal Learning Test; 6)
Modified Fuld Object Memory Evaluation; 7)Trail-mak-
ing test A&B; 8) RMB (Chinese currency) test. Norma-
tive data and detail description of these tests were
reported elsewhere [16, 24]. The neuropsychological
tests were administered by study psychometrists accord-
ing to the education level of each participant. All tests
were conducted in Chinese within 90 min.
Consensus diagnoses for cognitive function
After each clinical and neuropsychological assessment,
study neurologists and neuropsychologists (DD, QZ,
QG, and ZH) reviewed the functional, medical, neuro-
logical, psychiatric, and neuropsychological data and
reached a consensus for dementia, MCI and normal
cognition. DSM-IV criteria [25] was used to diagnose
dementia, while Petersen’s criteria [26] were considered
for a diagnosis of MCI. Participants diagnosed with
dementia were ineligible to the current study.
Olfactory identification test
“Sniffin’ Sticks” is a test of nasal chemosensory function
based on felt-tip pens that was devised by G. Kobal in
Erlangen, Germany. In its most elaborate version, it
comprises 3 tests of olfactory function (odor threshold,
odor discrimination, and odor identification), and takes
approximately 20 to 30 min for application [27]. The
SSST-12 is a rapid (approximately 6 min), portable,
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suited for repetitive and inexpensive screening of OI that
utilizes 12 common odors (orange, leather, cinnamon,
peppermint, banana, lemon, liquorice, coffee, cloves,
pineapple, rose and fish) presented in felt-tip sticks. The
SSST-12 has been validated for clinical use in several
European countries, such as Germany, United Kingdom,
Greece, etc. [17]. In China, only SSST-16 were used in
clinical PD studies, however, without validation [28, 29].
In the current study, we used the SSST-12 bought from
Burghart Medical Technology [30]. We translated the
list of odors into Chinese on the report sheet.
The administrator of OI test was blind for the cog-
nitive diagnosis of each participant. Before the test,
participants were reminded to stay away from chew-
ing gum, sweets or cigarettes. Testing was performed
in a quiet, air-conditioned room. A brief history in-
cluding questions related to the participant’s olfactory
experience, previous diseases, drug intake, occupation
and smoking habits were recorded. The administrator
was wearing cotton gloves when presenting the odors.
The opened odor sticks were positioned approxi-
mately 2 cm in front of both nostrils of each partici-
pant. Participants were then asked to sniff for no
longer than 3–4 s and to choose one of four answers
from a list that described best the odor. An interval
of 30 s was between the different sticks.
APOE genotype assessment
DNA was extracted from blood or saliva, collected from
the study participants. Apolipoprotein (APOE) genotyp-
ing was conducted by the TaqmanSNP method [31]. The
presence of at least one ε4 allele was treated as being
APOE-ε4 positive.
Statistical analysis
The categorical variables were expressed as frequencies
(%), and the continuous variables were expressed as
the mean and standard deviation (SD). The Pearson
Chi-squared test was used to compare the categorical
variables. The Student t-test, analysis of variance
(ANOVA) and generalized linear model (GLM) were
used to compare the continuous variables. We used
two multivariate logistic regression models to detect
the association between OI and cognitive function, by
adjusting for variables of age, gender and education
(model 1) and by adjusting additional confounding var-
iables, such as lifestyles (smoking, drinking and living
status), medical history (anxiety, depression, heart dis-
ease, hypertension and diabetes) and APOE-ε4 allele
(model 2). Risk was presented as odds ratio (OR) and
95 % confidence interval (CI). All of the P-values and
95 % CIs were estimated in a two-tailed tests. Differ-
ences were considered to be statistically significant at
P < 0.050. The data were analyzed using SAS 9.3 (SAS
Institute Inc., Cary, NC, USA).
Results
Characteristics of participants
From April 2010 to March 2011, the Shanghai Aging
Study consequently enrolled 1808 participants who had
completed both of the cognitive assessment and OI test.
Twenty-six were excluded due to the diagnosis of
dementia. Table 1 showed that, among 1782 participants,
818 (45.9 %) were men. The mean age of the participants
was 70.1(SD 7.1) years and mean year of education was
12.3(SD 3.9) years. Three hundred and forty-five
(19.4 %) participants were diagnosed as MCI. Character-
istics of age, education, MMSE scores, living alone,
history of hypertension, diabetes and depression were
found to be significantly different between groups with
cognitive normal and MCI. The average scores of OI of
all the participants were 8.0 (SD 2.1). The average OI
scores of participants with MCI [7.1(SD 2.3) scores]
were significantly lower than that of participants with
normal cognition [8.2 (SD 2.0) scores, p < 0.0001].
Normative data of olfactory identification scores
Table 2 described the normative data of OI scores in all
participants by gender and age groups. In each group
with different gender, the mean OI scores decreased by
increasing age (P trend < 0.0001). As for the males, the
mean OI scores were from 8.4 (SD1.9) in participants
aged 60–69 years, to 7.0 (SD 2.3) in participants aged
Table 1 Demographic, olfactory identification scores, lifestyles









Gender, male, n (%) 818(45.9) 659(45.9) 159(46.1) 0.939
Age, years, mean(SD) 70.1(7.1) 69.4(6.8) 73.0(7.8) <0.0001
Education, years, mean(SD) 12.3(3.9) 12.8(3.5) 10.4(4.9) <0.0001
MMSE, scores, mean(SD) 28.4(1.8) 28.7(1.5) 27.0(2.5) <0.0001
OI, scores, mean(SD) 8.0(2.1) 8.2(2.0) 7.1(2.3) <0.0001
Living alone, n (%) 145(8.2) 107(7.5) 38(11.1) 0.035
Cigarette smoking, n (%) 185(10.4) 141(9.9) 44(12.8) 0.117
Alcohol drinking, n (%) 142(8.0) 114(8.0) 28(8.2) 0.915
Heart disease, n (%) 194(10.9) 150(10.5) 44(12.8) 0.223
Hypertension, n (%) 962(54.0) 759(52.8) 203(58.8) 0.043
Diabetes, n (%) 247(13.9) 180(12.5) 67(19.5) 0.001
Anxiety, n (%) 42(2.4) 34(2.4) 8(2.3) 0.969
Depression, n (%) 277(15.6) 207(14.4) 70(20.4) 0.008
APOE-ε4 allele positive, n (%) 308(18.3) 251(18.4) 57(17.9) 0.837
P value is for the comparison between participants with cognitive normal vs. MCI
Abbreviation: SD standard deviation, MCI mild cognitive impairment, MMSE
Mini-Mental State examination, APOE Apolipoprotein, OI olfactory identification
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80 years and above. As for the females, the mean OI
scores were from 8.5 (SD1.8) in participants aged 60–69
years, to 6.9 (SD 2.4) in participants aged 80 years and
above. There was no significant difference between
males and females for the decreasing trend of OI scores
by increasing age (P = 0.254). The median and percentile
scores of OI were also showed in Table 2.
Association between olfactory identification scores and
cognitive function
Figure 1 showed that the mean OI scores of MCI and
cognitive normal groups decreased by increasing age (both
P trend < 0.0001). The mean OI scores of MCI group de-
creased more dramatically by increasing age than that of
group with cognitive normal (P < 0.0001). Figure 2 dem-
onstrated the correct percentages answered by partici-
pants with MCI and cognitive normal for each odor.
Three odors with highest correct percentages were coffee
(93.6 % for group with cognitive normal, 86.1 % for MCI
group), peppermint (91.9 % for group with cognitive
normal, 87.3 % for MCI group), and fish (84.6 % for group
with cognitive normal, 75.1 % for MCI group). Three
odors with lowest correct percentages were lemon
(54.8 %), cloves (52.1 %), and cinnamon (45.1 %) for group
Table 2 Description of olfactory identification scores in community-dwelling elderly by gender and age groups
Male Female
Age group, years 60–69 70–79 ≥80 P value 60–69 70–79 ≥80 P value P value (male vs. female)
No. of participants, n (%) 428(50.6) 307(36.3) 83(9.8) 522(49.7) 353 (33.6) 89(8.5)
Scores, Mean (SD) 8.4(1.9) 7.5(2.1) 7.0(2.3) <0.0001 8.5(1.8) 7.6(2.0) 6.9(2.4) <0.0001 0.254
Median (Min, Max) 8(0,12) 8(3,12) 8(0,12) 9(0,12) 8(0,12) 7(0,11)
Percentile (%)
10 6 5 4 6 5 4
20 7 6 5 7 6 5
30 8 7 6 8 7 6
40 8 7 7 8 7 7
50 9 8 7 9 8 7
60 9 8 8 9 8 8
70 9 9 8 10 9 8
80 10 9 9 10 9 9
90 11 10 9 11 10 10
Abbreviation: SD standard deviation; P value is for the comparison of scores of olfactory identification with increasing age
Fig. 1 Description of olfactory identification scores in community-dwelling elderly by different cognitions and age groups. Notes: Mean OI scores of
MCI and cognitive normal groups decreased by increasing age (both P trend < 0.0001). The mean OI scores of MCI group decreased more dramatically
by increasing age than that of group with normal cognition (P < 0.0001). Abbreviation: OI: olfactory identification; MCI: mild cognitive impairment; NC:
Normal cognition
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with cognitive normal, leather (45.8 %), liquorice (43.2 %)
and cinnamon (35.4 %) for MCI group. Participants with
MCI answered less correct percentages for each odor than
those with cognitive normal. Significant differences were
found in odor of peppermint (cognitive normal vs. MCI,
91.9 % vs. 87.3 %%, P = 0.015), orange (78.1 % vs. 70.4 %,
P = 0.003), pineapple (70.6 % vs. 63.8 %, P = 0.009), and
cinnamon (45.1 % vs. 35.4 %, P = 0.001), coffee (93.6 % vs.
86.1 %, P < 0.0001), fish (84.6 % vs. 75.1 %, P < 0.0001),
banana (68.0 % vs. 54.2 %, P < 0.0001), rose (65.3 % vs.
50.1 %, P < 0.0001), leather (58.7 % vs. 45.8 %, P < 0.0001),
and liquorice (56.2 % vs. 43.2 %, P < 0.0001).
The multivariate logistic model 1 indicated that, lower
OI score was an independent influence factor associated
with MCI (OR = 1.18, 95 % CI: 1.11–1.25), after adjusted
for age, gender and education. Additionally, after adjust-
ing for variables of age, gender, education, living alone,
cigarette smoking, alcohol drinking, anxiety, depres-
sion, heart disease, hypertension, diabetes, and APOE-
ε4 allele, model 2 also indicated that lower OI score
was a influence factor independently associated with
MCI (OR = 1.19; 95 % CI: 1.11–1.27) (Table 3).
Discussion
To our knowledge, this is the first epidemiological study
that reports the normative data of OI among community-
dwelling elderly in China by using the SSST-12. The main
finding of this community-based study was that, poor OI
was an independent factor associated with the cognitive
decline in elderly, after adjusting possible confounders.
Fig. 2 Correct percentages of olfactory identification in community-dwelling elderly with cognition normal and MCI. Notes: * represents “P < 0.050
and P > 0.0001”; ** represents “P < 0.0001”
Table 3 Odds ratios for olfactory identification score and other
confounders among participants with mild cognitive
impairment vs. cognitive normal
Variable Model 1
OR (95 % CI)
P value Model 2
OR (95 % CI)
P value
OI (score, decreasing) 1.18(1.11,1.25) <0.0001 1.19(1.11,1.27) <0.0001
Age (increasing) 1.05(1.03, 1.07) <0.0001 1.05(1.03, 1.07) <0.0001
Gender
(female vs. male)
0.77(0.60, 1.00) 0.053 0.85(0.63, 1.15) 0.284
Education year
(increasing)
0.88(0.86, 0.91) <0.0001 0.88(0.85, 0.91) <0.0001
Living alone 1.00(0.63, 1.59) 0.995
Cigarette smoking 1.57(0.99, 2.47) 0.053
Alcohol drinking 0.77(0.46, 1.28) 0.309
Heart disease 0.87(0.57, 1.32) 0.506
Hypertension 0.98(0.75, 1.29) 0.896
Diabetes 1.54(1.08, 2.20) 0.018
Anxiety 0.59(0.25, 1.39) 0.227




Model 1: multivariate logistic regression model, adjusted for age, gender
and education
Model 2: multivariate logistic regression model, adjusted for age, gender,
education, living alone, cigarette smoking, alcohol drinking, anxiety,
depression, heart disease, hypertension, diabetes, and Apolipoprotein-ε4
Abbreviation: OI olfactory identification, OR odds ratio, CI confidence interval
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The advantages of this study include community-based
design with large sample size, reliable diagnosis of cogni-
tive function based on comprehensive clinical and neuro-
psychological exams, and detailed influence factor profiles
(including APOE genotype) for each participant.
Some small-sampled case-control studies have re-
ported the relation between poor olfaction and AD/
MCI. AD patients were more impaired on OI and recog-
nition tasks than on odor detection thresholds task.
They were also more strongly impaired on higher-order
olfactory tasks involving specific cognitive processes
[32]. A study in Germany found that, 7/14 AD patients
and 4/8 individuals with MCI showed no olfactory
event-related potentials (tested by the SS), suggesting
hyposmia, while all comparison individuals had clearly
discernible responses [33]. Serby M et al. studied OI in
55 AD patients and 57 controls by using the UPSIT, and
found that OI performances were nearly 40 % lower in
mild AD patients than in controls [34]. A Hong Kong
study revealed that 12 probable AD cases identified
significantly fewer odors (tested by Olfactory Identifica-
tion Test) and had significantly higher olfactory thresh-
old (tested by Alcohol Sniff Test) than their age- and
education-matched normal controls [12]. OI (tested by
lexical-based OI, lexical-based picture identification,
picture-based OI, and odor-detection threshold) was re-
ported to be correlated with cognitive functions in indi-
viduals with preclinical AD compared with normal
control subjects before they showed any changes in daily
functioning [34, 35].
Some prospective studies, mostly in western countries,
demonstrated that older persons with impaired OI were
more apt to experience cognitive decline than those with
relatively preserved OI. The Mayo Clinic Study of Aging
followed the 1430 cognitively normal participants over a
mean 3.5 years, and observed an association between
decreasing olfactory identification with a decreasing
number of correct responses in Brief Smell Identification
Test (B-SIT) score, and a higher risk of amnestic MCI
(aMCI). Compared with the upper B-SIT quartile (quar-
tile [Q] 4, best scores), hazard ratios (HRs) (95 % CI)
were 1.12 (0.65–1.92) for Q3 (P = 0.680); 1.95 (1.25–3.03)
for Q2 (P = 0.003); and 2.18 (1.36–3.51) for Q1 (P = 0.001)
(worst scores; P for trend <0.001) after adjustment for
gender and education, with same age. The B-SIT score
also predicted progression from aMCI to AD, with a
significant dose-response with worsening B-SIT quartiles
[6]. The community-based longitudinal study of memory
and aging in the Japanese-American community in King
County, WA screened 1985 persons using the Cognitive
Abilities Screening Instrument (CASI) and the CC-SIT at
the baseline. After 2 years, the authors determined an OR
for cognitive decline (defined as loss of ≥5.15 points/100
on the CASI) of 0.90 (95%CI: 0.84–0.97) for an increasing
in each correct point on the CC-SIT [5]. Another
population-based study followed up 1920 older partici-
pants in the Epidemiology of Hearing Loss Study in
Beaver Dam, Wisconsin. Olfactory was measured by
the SDOIT, and the incident cognitive impairment was
defined as a MMSE of less than 24 or reported diagno-
sis of dementia. There was significant association be-
tween olfactory impairment at baseline and 5-year
incidence of cognitive impairment (OR = 3.72, 95 % CI:
2.31–5.99) after adjusting for possible confounders [2].
The association of OI with decline rate in different cog-
nitive domains was examined in 481 older participants
from the Rush Memory and Aging Project. Lower OI
score was related to lower function at baseline in each
cognitive domain, especially in perceptual speed and
episodic memory, after adjustment for age, sex, and
education [3]. One hundred seventy-three independent
residents of a continuing care retirement community
completed UPSIT and MMSE and the Executive
Interview (EXIT25) at baseline and were examined
twice over 3 years. It concluded that impaired OI non-
demented individuals was related to an AD-like mem-
ory impairment and an increased rate of cognitive de-
cline [36]. Swan GE et al. reported that, a total of 359
individuals were administered the BSIT for OI, and ver-
bal learning, memory, executive control and global
function for cognitive function. Impaired olfactory
function was associated with a greater 4.5-year decline
on several indices of verbal memory after adjustment
for baseline cognitive performance, by a multivariate
analysis [37]. Devanand DP et al. examined 90 outpa-
tients with MCI and 45 controls by UPSIT for OI at
baseline, and diagnosed incident AD by 2 years. In
patients with high MMSE (≥27 of 30), low olfaction
with lack of awareness was explored a significant pre-
dictor of AD. At follow-up, olfaction scores of 30–35
showed moderate to strong sensitivity and specificity
for diagnosis of AD [8].
APOE genotype was identified as an important factor
interacting with olfaction. Murphy C et al. have indi-
cated that APOE-ε4 allele is related to OI deficits (tested
by SDOIT) in 27 non-demented older persons [38].
Olfactory dysfunction (tested by CC-SIT) in the presence
of one or more APOE-ε4 alleles was related to a 4.9
times the risk of cognitive decline in the longitudinal
study of memory and aging in the Japanese-American
community in King County [5]. A study in China used
CC-SIT to assess OI performance in 28 patients with
MCI and the 30 controls. They found that individuals
with APOE-ε4 allele were able to identify less odors than
that of the subjects without APOE-ε4 allele (P < 0.010).
It suggested that the decreased OI in MCI may be an
indicator for the early diagnosis of AD, and APOE geno-
type may be a portion of the basis of OI decline [15].
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Our study did not find the significant contribution of
APOE-ε4 allele to cognitive decline through the multi-
variate logistic regression model. The independent asso-
ciation between the poor OI and cognitive decline were
explored, after adjusting the possible confounders
including APOE genotype (Table 3).
There were several mechanisms or explanations for
the association between olfactory dysfunction and cogni-
tion impairment. OI is more strictly involved in cogni-
tive functions since it is processed in the mesial
structures of the temporal lobe. The olfactory threshold,
however, is mostly influenced by peripheral deficits of
the smell sense. It has been shown that typical lesions of
AD (i.e., amyloid core and neurofibrillar tangles) were
already detectable in the preclinical stages in central
olfactory pathways [39]. With recent reports in patho-
logical and brain imaging analyses, it has been found
that neurodegenerative changes, including the appear-
ance of Lewy bodies, were commonly observed in
regions of the brain which responsible for olfactory per-
ception, such as the amygdala, hippocampus, and orbito-
frontal cortex. These changes are apparent from the
earliest stages of dementia [40, 41]. Kjelvik G et al stud-
ied 12 patients with aMCI, 6 with early AD, and 30 con-
trols. They reported that the aMCI/AD group with
reduced OI ability (measured by B-SIT and SSIT), had
significantly smaller hippocampal volume than that of
the patient group with OI scores > 50 %. There was a
significant association between OI scores and hippocam-
pal volume only in the patient group. The results sug-
gested that the decrease in the hippocampus size in
connection with early AD was related to more with loss
of OI ability rather than loss of memory, thus demon-
strating that impaired OI is an early indicator of medial
temporal lobe degeneration [42].
Our study also explored an interesting finding that,
some odors, such as coffee, fish, banana, rose, leather,
and liquorice were identified more significantly different
between individuals with MCI and cognitive normal,
than odors of lemon and cloves. It suggests that some
odors might be the sensitive indicators for the early
stage of cognitive decline, while some might be not. The
transformational mechanism of stimulation by different
odors may need more attention.
Olfactory function includes threshold, discrimination,
identification and olfactory recognition [11]. In the current
study, we only studied the OI in our study participants. It
was reported that odor discrimination and identification
performance correlated more significantly than detection
thresholds with performance on neuropsychological tests
[9]. Thus other domains of olfaction were also important,
especially discrimination, which could also be useful as the
early predictor of AD. The second limitation is the lack of
assessment for parkinsonism and PD, because the olfactory
dysfunction occurs in early stages of clinical PD and in
asymptomatic relative of PD patient with a prevalence of
approximately 90 % [43]. Other limitations include the
cross-sectional study design, which cannot determine the
causal association, so it is possible that the poor OI was
the early symptom of MCI rather than a risk factor; and
the potentially unmeasured confounding factors, which
may influence the results.
Conclusion
Our study suggests that poor OI may be associated with
MCI in elderly population. Follow-up assessment of our
Shanghai Aging Study cohort will be carried out to
confirm olfactory dysfunction may be an important
predictor for cognitive impairment, as well as its patho-
logical mechanism.
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SDOIT: San Diego odor identification test; SOIT: Scandinavian odor-
identification test; SS: Sniffin’ sticks; SSST: Sniffin’ sticks screening test;
UPSIT: University of Pennsylvania smell identification test; ZSAS: Zung self-
rating anxiety scale
Acknowledgments
The authors thank Dr. Minhua Shao for her technical assistance in the APOE
genotype assays, Zhaolan Ding, Meihua Jin, Meirong Chen, Zeya Wang,
Meizheng Shi, Jingping Ye, Meiping He, Lanfang Yu, Deping Chen, Fusheng
Gong, Meili Shi, Wenying Zhou, Shumin Chen, Xiudi Xu, Meiling Huang,
Linghua Ding, Wenfan Zhu, Zhi Zhou, Xiaoying Liu, FuqinGao, Peng Gong,
Lin Lu, Meng Wang, Ting Zhang, Yaru Guo, Xiaoli Jin, Shiqi Li, Qiongyi Xu,
and Yiping Wang for their efforts to the study, and all the participants for
their cooperation.
Funding
This project was funded by the Science & Technology Committee, Shanghai,
China (09DZ1950400).
Availability of data and materials
We can share our relevant raw data supporting our findings. If any scientist
who wish to use them for non-commercial purposes, without breaching
participant confidentiality, he/her can contact us directly, and we will share
our raw data freely with he/her.
Authors’ contributions
DD participated in the design of the study and subject recruitment and the
data collection, edited the manuscript and read and approved the final
manuscript. XL participated in the data collection and data input and data
analysis, drafted the manuscript, edited the manuscript and read and
approved the final manuscript. QZ and QG both participated in the design
of the study and subject recruitment, edited the manuscript, and read and
approved the final manuscript. JL participated in the design of the study,
edited the manuscript and read and approved the final manuscript. ZH
participated in the design of the study, edited the manuscript and read and
approved the final manuscript.
Liang et al. BMC Neurology  (2016) 16:199 Page 7 of 9
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Huashan
Hospital, Fudan University, Shanghai, China. All participants and/or their legal
guardian gave their written informed consent to participate in the study.
Author details
1Institute of Neurology, Huashan Hospital, Fudan University, WHO
Collaborating Center for Research and Training in Neurosciences, Shanghai
200040, China. 2Department of Biostatistics, School of Public Health, Fudan
University, Shanghai 200032, China. 3The Key Laboratory of Public Health
Safety, Fudan University, Shanghai 200032, China. 4National Clinical Research
Center for Aging Diseases, Shanghai 200040, China.
Received: 18 March 2016 Accepted: 15 October 2016
References
1. Attems J, Walker L, Jellinger KA. Olfaction and aging: a mini-review.
Gerontology. 2015;61:485–90.
2. Schubert CR, Carmichael LL, Murphy C, Klein BE, Klein R, Cruickshanks KJ.
Olfaction and the 5-year incidence of cognitive impairment in an
epidemiological study of older adults. J Am GeriatrSoc. 2008;56:1517–21.
3. Wilson RS, Arnold SE, Tang Y, Bennett DA. Odor identification and decline in
different cognitive domains in old age. Neuroepidemiology. 2006;26:61–7.
4. Sohrabi HR, Bates KA, Rodrigues M, Taddei K, Laws SM, Lautenschlager NT,
Dhaliwal SS, Johnston AN, MacKay-Sim A, Gandy S, Foster JK, Martins RN.
Olfactory dysfunction is associated with subjective memory complaints in
community-dwelling elderly individuals. J Alzheimers Dis. 2009;17:135–42.
5. Graves AB, Bowen JD, Rajaram L, McCormick WC, Mccurry SM, Schellenberg
GD, Larson EB. Impaired olfaction as a marker for cognitive decline: interaction
with apolipoprotein e epsilon4 status. Neurology. 1999;53:1480–7.
6. Roberts RO, Christianson TJ, Kremers WK, Mielke MM, Machulda MM,
Vassilaki M, Alhurani RE, Geda YE, Knopman DS, Petersen RC. Association
between olfactory dysfunction and amnestic mild cognitive impairment
and Alzheimer disease dementia. JAMA Neurol. 1-9. doi: 10.1001/
jamaneurol.2015.2952. [Epub ahead of print]
7. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K,
Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment.
Arch Neurol. 2001;58:1985–92.
8. Devanand DP, Micheals-Marston KS, Liu X, Pelton GH, Padilla M, Marder K,
Bell K, Stern Y, Mayeux R. Olfactory deficits in patients with mild cognitive
impairment predict Alzheimer’s disease at follow-up. Am J Psychiatry. 2000;
157:1399–405.
9. Djordjevic J, Jones-Gotman M, De Sousa K, Chertkow H. Olfactory in
patients with mild cognitive impairment and Alzheimer’s disease. Neurology
Aging. 2008;29:693–706.
10. Yoon JH, Kim M, Moon SY, Yong SW, Hong JM. Olfactory function and
neuropsychological profile to differentiate dementia with lewy bodies from
Alzheimer’s disease in patients with mild cognitive impairment: a 5-year
follow-up study. J Neurologial Sciences. 2015;355:174–9.
11. Eibenstein A, Fioretti AB, Lena C, Rosati N, Amabile G, Fusetti M. Modern
psychophysical tests to assess olfactory function. NeurolSci. 2005;26:147–55.
12. Chan A, Tam J, Murphy C, Chiu H, Lam L. Utility of olfactory identification
test for diagnosing Chinese patients with alzheimer’s disease. J
ClinExpNeuropsychol. 2002;24:251–9.
13. Liu HC, Wang SJ, Lin KP, Lin KN, Fuh JL, Teng EL. Performance on a smell
screening test (the MODSIT): a study of 510 predominantly illiterate Chinese
subjects. Physiol Behav. 1995;58:1251–5.
14. Population of over-60-yr-olds reaches 212 million. 2015. Available at:
http://www.newsgd.com/news/2015-06/15/content_126401545.htm.
Accessed 13 Jan 2016.
15. Wang QS, Tian L, Huang YL, Qin S, He LQ, Zhou JN. Olfactory identification
and apolipoprotein e epsilon 4 allele in mild cognitive impairment. Brain
Res. 2002;951:77–81.
16. Ding D, Zhao Q, Guo Q, Meng H, Wang B, Luo J, Mortimer JA, Borenstein
AR, Hong Z. Prevalence of mild cognitive impairment in an urban
community in China: a cross-sectional analysis of the Shanghai aging study.
Alzheimers Dement. 2015;11:300–9.
17. Hummel T, Konnerth CG, Rosenheim K, Kobal G. Screening of olfactory
function with a four-minute odor identification test: reliability, normative
data, and investigations in patients with olfactory loss. Ann
OtolRhinolLaryngol. 2001;110:976–81.
18. Ding D, Zhao Q, Guo Q, Meng H, Wang B, Yu P, Luo J, Zhou Y, Yu L, Zheng
L, Chu S, Mortimer JA, Borenstein AR, Hong Z. The Shanghai aging study:
study design, baseline characteristics, and prevalence of dementia.
Neuroepidemiology. 2014;43:114–22.
19. Zung WW. A rating instrument for anxiety disorders. Psychosomatics. 1971;
12:371–9.
20. Zhang J, Norvilitis JM. Measuring chinese psychological well-being with
western developed instruments. J Pers Assess. 2002;79:492–511.
21. Morris JC. The clinical dementia rating (cdr). current version and scoring
rules. Neurology. 1993;43:2412–4.
22. Lim WS, Chong MS, Sahadevan S. Utility of the clinical dementia rating in
asian populations. Clin Med Res. 2007;5:61–70.
23. Lawton MP, Brody EM. Assessment of older people: self-maintaining and
instrumental activities of daily living. Gerontologist. 1969;9:179–86.
24. Zhang MY, Katzman R, Salmon D, Jin H, Cai GJ, Wang ZY, Qu GY, Grant I, Yu
E, Levy P, Klauber MR, Liu WT. The prevalence of dementia and alzheimers-
disease in shanghai, china - impact of age, gender, and education. Ann
Neurol. 1990;27:428–37.
25. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders, vol. 4. Washington: American Psychiatric Association; 1994.
p. 143–7.
26. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med.
2004;256:183–94.
27. Kobal G, Klimek L, Wolfensberger M, Gudziol H, Temmel A, Owen CM,
Seeber H, Pauli E, Hummel T. Multicenter investigation of 1,036 subjects
using a standardized method for the assessment of olfactory function
combining tests of odor identification, odor discrimination, and olfactory
thresholds. Eur Arch Otorhinolaryngol. 2000;257:205–11.
28. Chen W, Chen S, Kang WY, Li B, Xu ZM, Xiao Q, Liu J, Wang Y, Wang G,
Chen SD. Application of odor identification test in Parkinson’s disease in
china: a matched case-control study. J NeurolSci. 2012;316:47–50.
29. Chen W, Tan YY, Hu YY, Zhan WW, Wu L, Lou Y, Wang X, Zhou Y, Huang P,
Gao Y, Xiao Q, Chen SD. Combination of olfactory test and substantia nigra
transcranial sonopraphy in the differential diagnosis of Parkinson’s disease: a
pilot study from china. TranslNeurodegener. 2012;1:25.
30. TinsdalerWeg 175, Burghart Medical Technology, Hamburg, Germany. http://
www.burghart.net. Accessed 13 Jan 2016.
31. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG. Genetic analysis of
radiation-induced changes in human gene expression. Nature. 2009;459:
587–91.
32. Rahayel S, Frasnelli J, Joubert S. The effect of alzheimer’s disease and
parkinson’s disease on olfaction: a meta-analysis. Behav Brain Res. 2012;
231:60–74.
33. Peters JM, Hummel T, Kratzsch T, Lotsch J, Skarke C, Frolich L. Olfactory
function in mild cognitive impairment and alzheimer’s disease: an
investigation using psychophysical and electrophysiological techniques. Am
J Psychiatry. 2003;160:1995–2002.
34. Serby M, Larson P, Kalkstein D. The nature and course of olfactory deficits in
alzheimers-disease. Am J Psychiat. 1991;148:357–60.
35. Morgan CD, Nordin S, Murphy C. Odor identification as an early marker for
alzheimers-disease - impact of lexical functioning and detection sensitivity. J
ClinExpNeuropsyc. 1995;17:793–803.
36. Royall DR, Chiodo LK, Polk MJ, Jaramillo CJ. Severe dysosmia is specifically
associated with Alzheimer-like memory deficits in nondemented elderly
retirees. Neuroepidemiology. 2002;21:68–73.
37. Swan GE, Carmelli D. Impaired olfaction predicts cognitive decline in
nondemented older adults. Neuroepidemiology. 2002;21:58–67.
38. Murphy C, Bacon AW, Bondi MW, Salmon DP. Apolipoprotein e status is
associated with odor identification deficits in nondemented older persons.
Ann N Y AcadSci. 1998;855:744–50.
39. Morris JC, Storandt M, Miller JP, Mckeel DW, Price JL, Rubin EH, Berg L. Mild
cognitive impairment represents early-stage alzheimer disease. Arch Neurol.
2001;58:397–405.
Liang et al. BMC Neurology  (2016) 16:199 Page 8 of 9
40. Hubbard PS, Esiri MM, Reading M, Mcshane R, Nagy Z. Alpha-synuclein
pathology in the olfactory pathways of dementia patients. J Anat. 2007;
211:117–24.
41. Silveira-Moriyama L, Holton JL, Kingsbury A, Ayling H, Petrie A, Sterlacci W,
Poewe W, Maier H, Lees AJ, Revesz T. Regional differences in the severity of
lewy body pathology across the olfactory cortex. NeurosciLett. 2009;453:77–80.
42. Kjelvik G, Saltvedt I, White LR, Stenumgard P, Sletvold O, Engedal K, Skatun
K, Lyngvaer AK, Steffenach HA, Haberg AK. The brain structural and
cognitive basis of odor identification deficits in mild cognitive impairment
and alzheimer’s disease. BmcNeurol. 2014;14:168.
43. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory
dysfunction in early stage treated and untreated idiopathic Parkinson’s
disease. J Neurol Neurosurg Psychiatry. 1992;55:138–42.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Liang et al. BMC Neurology  (2016) 16:199 Page 9 of 9
